Beta Drugs Ltd Share Price

Pharmaceuticals - Indian - Bulk DrugsNSE
₹2,295.00
-104.20-4.34% (1D)
As on 20 Aug 2026 at 15:57
As of 20 Aug 2026 at 15:57, Beta Drugs Ltd is trading at ₹2,295.00. The 52-week range stands at ₹990.10–₹2,807.90, with a market cap of ₹2.54 thousand crore. At a P/E of 158.71 and a dividend yield of 0.00%, it is a small-cap stock in the Pharmaceuticals sector.

BETA Price Chart

Market Cap
₹2.54K Cr
PE Ratio
158.71
ROCE
10.56%

Beta Drugs Ltd Performance

Beta Drugs Ltd Fundamentals

Market Cap₹2.54K Cr
ROE9.58%
P/E Ratio (TTM)158.71
EPS (TTM)₹14.46
P/B Ratio16.90
Dividend Yield0.00%
Industry P/E92.64
Book Value₹135.76
Debt to Equity0.87
Face Value₹10

Beta Drugs Ltd Shareholding Pattern

Promoter59.1%
Foreign Institutions1%
Mutual Funds0%
Domestic Institutions6.2%
Public33.6%

Beta Drugs Ltd Financial Statements

No data for this view.

Beta Drugs Ltd Peer Comparison

StocksLTP(₹)Market Cap(Cr)
Sun Pharmaceutical Industries Ltd
₹1,901.00
1.00(+0.05%)
4,56,113.6
Torrent Pharmaceuticals Ltd
₹4,994.90
-18.10(-0.36%)
1,89,989.9
Cipla Ltd
₹1,437.65
15.65(+1.10%)
1,16,141.0
Lupin Ltd
₹2,203.10
-21.90(-0.98%)
1,00,732.9
Dr Reddys Laboratories Ltd
₹1,181.35
11.35(+0.97%)
98,604.4

About Beta Drugs

Beta Drugs Limited was incorporated as a private limited company with the name 'Beta Drugs Private limited' at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to public limited company and the name of the company was changed to 'Beta Drugs Limited' on August 11, 2017 Beta Drugs is a part of Adley Group. Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India. The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014. The company is primarily engaged in the manufacturing of oncology products. The Company's products range from anti-cancer tablets, capsules, injections and lyophilized injections. The Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease. The Company set up the first Oncology Unit in Adley Formulations Pvt Ltd. in 2008. It set up a new 'state of the art' manufacturing facility for oncology formulations in 2014; developed in-house Albumin bound Paclitaxel in 2015; started in-house API Plant - Adley Labs in 2017. In October, 2017, the Company came up with a Public Issue of 22,96,000 Equity Shares by raising equity capital aggregating Rs 19.5 Crores. The Company set up an Oncology Plant in Uzbekistan in 2018. In 2020, the Company launched GEM-RTU, ADLEAP, ADLANTE, BEXINIB; launched 1st Indian Brand of Dasatinib, BEEDAN. In 2025, the Company launched 1st Indian brand of Sunitinib, ADSUNIB.

Parent Organisation
Founded2005
Managing DirectorRahul Batra
NSE SymbolBETA

Beta Drugs Ltd Resistance and Support levels

R32,504.40R22,463.91R12,438.89S12,357.91S22,332.89S32,292.402,295.00

Beta Drugs Ltd Technicals

Current Price
₹2,295.00 ₹104.20 (-4.34%)
Bearish
6
Bullish
6
  • 20 Day3.9%
  • 50 Day4.7%
  • 100 Day17.8%
  • 200 Day28.9%

Beta Drugs Ltd Latest News

View More
16 JUL 2026 | Thursday
Beta Drugs to hold board meeting
12 MAY 2026 | Tuesday
Beta Drugs to conduct board meeting

2026

Board MeetingAnnounced
Board MeetingAnnounced
Board MeetingAnnounced
Board MeetingAnnounced
Board MeetingAnnounced
Board MeetingAnnounced

Frequently asked questions

The share price of Beta Drugs Ltd is ₹2,295.00 as of 20 Aug 2026 at 15:57.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now